These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 23910619)

  • 1. Treatment of early diffuse systemic sclerosis skin disease.
    Frech TM; Shanmugam VK; Shah AA; Assassi S; Gordon JK; Hant FN; Hinchcliff ME; Steen V; Khanna D; Kayser C; Domsic RT
    Clin Exp Rheumatol; 2013; 31(2 Suppl 76):166-71. PubMed ID: 23910619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset.
    Mendoza FA; Nagle SJ; Lee JB; Jimenez SA
    J Rheumatol; 2012 Jun; 39(6):1241-7. PubMed ID: 22467932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current approaches to the management of early active diffuse scleroderma skin disease.
    Nihtyanova SI; Denton CP
    Rheum Dis Clin North Am; 2008 Feb; 34(1):161-79; viii. PubMed ID: 18329538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS).
    Herrick AL; Pan X; Peytrignet S; Lunt M; Hesselstrand R; Mouthon L; Silman A; Brown E; Czirják L; Distler JHW; Distler O; Fligelstone K; Gregory WJ; Ochiel R; Vonk M; Ancuţa C; Ong VH; Farge D; Hudson M; Matucci-Cerinic M; Balbir-Gurman A; Midtvedt Ø; Jordan AC; Jobanputra P; Stevens W; Moinzadeh P; Hall FC; Agard C; Anderson ME; Diot E; Madhok R; Akil M; Buch MH; Chung L; Damjanov N; Gunawardena H; Lanyon P; Ahmad Y; Chakravarty K; Jacobsen S; MacGregor AJ; McHugh N; Müller-Ladner U; Riemekasten G; Becker M; Roddy J; Carreira PE; Fauchais AL; Hachulla E; Hamilton J; İnanç M; McLaren JS; van Laar JM; Pathare S; Proudman S; Rudin A; Sahhar J; Coppere B; Serratrice C; Sheeran T; Veale DJ; Grange C; Trad GS; Denton CP
    Ann Rheum Dis; 2017 Jul; 76(7):1207-1218. PubMed ID: 28188239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis.
    Nevskaya T; Zheng B; Baxter CA; Ramey DR; Pope JE; Baron M;
    Rheumatology (Oxford); 2020 Jul; 59(7):1715-1724. PubMed ID: 31774531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis.
    Clements PJ; Roth MD; Elashoff R; Tashkin DP; Goldin J; Silver RM; Sterz M; Seibold JR; Schraufnagel D; Simms RW; Bolster M; Wise RA; Steen V; Mayes MD; Connelly K; Metersky M; Furst DE;
    Ann Rheum Dis; 2007 Dec; 66(12):1641-7. PubMed ID: 17485423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease.
    Boulos D; Ngian GS; Rajadurai A; Elford K; Stevens W; Proudman S; Owen C; Roddy J; Nikpour M; Youssef P; Hill C; Sahhar J
    Int J Rheum Dis; 2017 Apr; 20(4):481-488. PubMed ID: 28337853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study.
    Su TI; Khanna D; Furst DE; Danovitch G; Burger C; Maranian P; Clements PJ
    Arthritis Rheum; 2009 Dec; 60(12):3821-30. PubMed ID: 19950289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silent myocarditis in systemic sclerosis detected by cardiovascular magnetic resonance using Lake Louise criteria.
    Mavrogeni S; Koutsogeorgopoulou L; Karabela G; Stavropoulos E; Katsifis G; Raftakis J; Plastiras S; Noutsias M; Markousis-Mavrogenis G; Kolovou G
    BMC Cardiovasc Disord; 2017 Jul; 17(1):187. PubMed ID: 28716007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse scleroderma.
    Sultan N; Pope JE; Clements PJ;
    Rheumatology (Oxford); 2004 Apr; 43(4):472-8. PubMed ID: 14679295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trigeminal neuropathy responding to systemic corticosteroids and methotrexate in a patient with diffuse cutaneous systemic sclerosis.
    Miguel D; Darr-Foit S; Tittelbach J; Elsner P
    Eur J Dermatol; 2017 Feb; 27(1):82-83. PubMed ID: 27748258
    [No Abstract]   [Full Text] [Related]  

  • 12. Comment on: A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis.
    Herrick AL; Lunt M; Silman AJ; Denton CP
    Rheumatology (Oxford); 2010 Aug; 49(8):1607-8; author reply 1608. PubMed ID: 20427293
    [No Abstract]   [Full Text] [Related]  

  • 13. A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis: the UPSIDE study protocol.
    Spierings J; van Rhenen A; Welsing PM; Marijnissen AC; De Langhe E; Del Papa N; Dierickx D; Gheorghe KR; Henes J; Hesselstrand R; Kerre T; Ljungman P; van de Loosdrecht AA; Marijt EW; Mayer M; Schmalzing M; Schroers R; Smith V; Voll RE; Vonk MC; Voskuyl AE; de Vries-Bouwstra JK; Walker UA; Wuttge DM; van Laar JM
    BMJ Open; 2021 Mar; 11(3):e044483. PubMed ID: 33737437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis.
    Sato S; Fujimoto M; Hasegawa M; Komura K; Yanaba K; Hayakawa I; Matsushita T; Takehara K
    Rheumatology (Oxford); 2004 Oct; 43(10):1261-6. PubMed ID: 15266059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis.
    Le EN; Wigley FM; Shah AA; Boin F; Hummers LK
    Ann Rheum Dis; 2011 Jun; 70(6):1104-7. PubMed ID: 21378404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using Autoantibodies and Cutaneous Subset to Develop Outcome-Based Disease Classification in Systemic Sclerosis.
    Nihtyanova SI; Sari A; Harvey JC; Leslie A; Derrett-Smith EC; Fonseca C; Ong VH; Denton CP
    Arthritis Rheumatol; 2020 Mar; 72(3):465-476. PubMed ID: 31682743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature.
    Pokeerbux MR; Giovannelli J; Dauchet L; Mouthon L; Agard C; Lega JC; Allanore Y; Jego P; Bienvenu B; Berthier S; Mekinian A; Hachulla E; Launay D
    Arthritis Res Ther; 2019 Apr; 21(1):86. PubMed ID: 30944015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrence of progressive skin involvement following discontinuation or dose reduction of Mycophenolate Mofetil treatment in patients with diffuse Systemic Sclerosis.
    Mendoza FA; Lee-Ching C; Jimenez SA
    Semin Arthritis Rheum; 2020 Feb; 50(1):135-139. PubMed ID: 31311679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective role of interleukin-6 in systemic sclerosis gastrointestinal tract involvement: case report and review of the literature.
    Frech TM; Hudson M
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S179-81. PubMed ID: 26339896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group.
    Sánchez-Cano D; Ortego-Centeno N; Callejas JL; Fonollosa Plá V; Ríos-Fernández R; Tolosa-Vilella C; Espinosa-Garriga G; Colunga-Argüelles D; Egurbide-Arberas MV; Rubio-Rivas M; Freire M; Ríos-Blanco JJ; Trapiella-Martínez L; Rodríguez-Carballeira M; Marín-Ballvé A; Pla-Salas X; Simeón-Aznar CP
    Rheumatol Int; 2018 Mar; 38(3):363-374. PubMed ID: 29322341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.